Which has preferable valuation & earnings, MBX or IVA?

MBX Biosciences has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.41 N/A Inventiva $5.07M 134.72 -$400.67M N/A N/A

Is MBX or IVA more profitable?

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Inventiva N/A N/A N/A

Does the media refer more to MBX or IVA?

In the previous week, MBX Biosciences had 4 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for MBX Biosciences and 5 mentions for Inventiva. MBX Biosciences' average media sentiment score of 0.77 beat Inventiva's score of 0.09 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HCM or IVA?

HUTCHMED has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.29 $456.91M N/A N/A Inventiva $5.07M 134.72 -$400.67M N/A N/A

Is HCM or IVA more profitable?

Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Inventiva N/A N/A N/A

Does the media favor HCM or IVA?

In the previous week, Inventiva had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Inventiva and 3 mentions for HUTCHMED. Inventiva's average media sentiment score of 0.09 beat HUTCHMED's score of 0.02 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, SUPN or IVA?

Supernus Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Supernus Pharmaceuticals $718.95M 3.40 -$38.55M -$1.92 N/A Inventiva $5.07M 134.72 -$400.67M N/A N/A

Does the media refer more to SUPN or IVA?

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 5 mentions for Inventiva. Supernus Pharmaceuticals' average media sentiment score of 0.33 beat Inventiva's score of 0.09 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, IVA or LQDA?

Liquidia has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 134.72 -$400.67M N/A N/A Liquidia $158.32M 15.16 -$68.92M $1.37 19.57

Is IVA or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Inventiva's net margin of 0.00%. Liquidia's return on equity of 149.65% beat Inventiva's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Liquidia 30.74% 149.65% 36.30%

Does the media refer more to IVA or LQDA?

In the previous week, Liquidia had 31 more articles in the media than Inventiva. MarketBeat recorded 36 mentions for Liquidia and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.09 beat Liquidia's score of 0.00 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Liquidia 16 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, IVA or HRMY?

Harmony Biosciences has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 134.72 -$400.67M N/A N/A Harmony Biosciences $868.45M 2.48 $158.69M $3.08 12.02

Does the media prefer IVA or HRMY?

In the previous week, Harmony Biosciences had 12 more articles in the media than Inventiva. MarketBeat recorded 17 mentions for Harmony Biosciences and 5 mentions for Inventiva. Harmony Biosciences' average media sentiment score of 0.85 beat Inventiva's score of 0.09 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Harmony Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inventiva (IVA) Competitors

$2.90 +0.04 (+1.22%)

As of 11:01 AM Eastern

Compare

IVA vs. MBX, HCM, SUPN, LQDA, and HRMY

Should you buy Inventiva stock or one of its competitors? Inventiva's main competitors and comparable companies include MBX Biosciences (MBX), HUTCHMED (HCM), Supernus Pharmaceuticals (SUPN), Liquidia (LQDA), and Harmony Biosciences (HRMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inventiva compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

MBX Biosciences has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Inventiva	$5.07M	134.72	-$400.67M	N/A	N/A

19.1% of Inventiva shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MBX Biosciences currently has a consensus target price of $87.00, suggesting a potential upside of 77.55%. Inventiva has a consensus target price of $15.86, suggesting a potential upside of 452.51%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

In the previous week, MBX Biosciences had 4 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for MBX Biosciences and 5 mentions for Inventiva. MBX Biosciences' average media sentiment score of 0.77 beat Inventiva's score of 0.09 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Inventiva's return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Inventiva	N/A	N/A	N/A

Summary

Inventiva beats MBX Biosciences on 9 of the 13 factors compared between the two stocks.

How does Inventiva compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

HUTCHMED has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.29	$456.91M	N/A	N/A
Inventiva	$5.07M	134.72	-$400.67M	N/A	N/A

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

HUTCHMED currently has a consensus price target of $14.87, suggesting a potential upside of 10.12%. Inventiva has a consensus price target of $15.86, suggesting a potential upside of 452.51%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Inventiva had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Inventiva and 3 mentions for HUTCHMED. Inventiva's average media sentiment score of 0.09 beat HUTCHMED's score of 0.02 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Inventiva	N/A	N/A	N/A

HUTCHMED has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Inventiva beats HUTCHMED on 10 of the 12 factors compared between the two stocks.

How does Inventiva compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Supernus Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 5 mentions for Inventiva. Supernus Pharmaceuticals' average media sentiment score of 0.33 beat Inventiva's score of 0.09 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Supernus Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.40	-$38.55M	-$1.92	N/A
Inventiva	$5.07M	134.72	-$400.67M	N/A	N/A

Inventiva has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Inventiva	N/A	N/A	N/A

Supernus Pharmaceuticals currently has a consensus target price of $62.40, suggesting a potential upside of 48.54%. Inventiva has a consensus target price of $15.86, suggesting a potential upside of 452.51%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

19.1% of Inventiva shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Inventiva beats Supernus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Inventiva compare to Liquidia?

Inventiva (NASDAQ:IVA) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Inventiva has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Inventiva presently has a consensus price target of $15.86, suggesting a potential upside of 452.51%. Liquidia has a consensus price target of $83.69, suggesting a potential upside of 212.17%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts plainly believe Inventiva is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Liquidia had 31 more articles in the media than Inventiva. MarketBeat recorded 36 mentions for Liquidia and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.09 beat Liquidia's score of 0.00 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Liquidia	16 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Liquidia has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	134.72	-$400.67M	N/A	N/A
Liquidia	$158.32M	15.16	-$68.92M	$1.37	19.57

Liquidia has a net margin of 30.74% compared to Inventiva's net margin of 0.00%. Liquidia's return on equity of 149.65% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Liquidia	30.74%	149.65%	36.30%

Summary

Inventiva beats Liquidia on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Harmony Biosciences?

Inventiva (NASDAQ:IVA) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Inventiva has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, Harmony Biosciences had 12 more articles in the media than Inventiva. MarketBeat recorded 17 mentions for Harmony Biosciences and 5 mentions for Inventiva. Harmony Biosciences' average media sentiment score of 0.85 beat Inventiva's score of 0.09 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Harmony Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	134.72	-$400.67M	N/A	N/A
Harmony Biosciences	$868.45M	2.48	$158.69M	$3.08	12.02

Harmony Biosciences has a net margin of 18.88% compared to Inventiva's net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Harmony Biosciences	18.88%	20.06%	14.15%

Inventiva presently has a consensus target price of $15.86, suggesting a potential upside of 452.51%. Harmony Biosciences has a consensus target price of $47.44, suggesting a potential upside of 28.12%. Given Inventiva's stronger consensus rating and higher probable upside, equities analysts clearly believe Inventiva is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

19.1% of Inventiva shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Harmony Biosciences beats Inventiva on 9 of the 15 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$693.74M	$12.35B	$7.25B	$13.04B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	N/A	807.81	275.44	25.51
Price / Sales	136.36	748.69	562.05	79.58
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-13.20	9.26	10.64	6.00
Net Income	-$400.67M	$2.83B	$3.49B	$380.50M
7 Day Performance	-13.80%	-3.62%	-3.21%	-3.35%
1 Month Performance	-25.13%	-7.66%	-7.65%	-6.23%
1 Year Performance	-41.43%	-5.44%	2.92%	-3.96%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.9679 of 5 stars	$2.91 +1.2%	$15.86 +445.9%	-37.7%	$693.74M	$5.07M	N/A	73	Short Interest Increase
MBX MBX Biosciences	2.8269 of 5 stars	$55.47 -5.3%	$83.89 +51.2%	+237.9%	$2.69B	N/A	N/A	63	Analyst Forecast
HCM HUTCHMED	1.2766 of 5 stars	$14.73 +2.9%	$14.87 +0.9%	-12.3%	$2.57B	$549.12M	N/A	1,796
SUPN Supernus Pharmaceuticals	3.5958 of 5 stars	$41.73 -2.4%	$62.83 +50.6%	-13.2%	$2.43B	$718.95M	N/A	778	News Coverage
LQDA Liquidia	4.4371 of 5 stars	$26.19 -5.3%	$83.69 +219.6%	+12.8%	$2.34B	$450.91M	19.09	216	Trending News Analyst Forecast Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. MBX, HCM, SUPN, LQDA, and HRMY

How does Inventiva compare to MBX Biosciences?

Summary

How does Inventiva compare to HUTCHMED?

Summary

How does Inventiva compare to Supernus Pharmaceuticals?

Summary

How does Inventiva compare to Liquidia?

Summary

How does Inventiva compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. MBX, HCM, SUPN, LQDA, and HRMY

How does Inventiva compare to MBX Biosciences?

Which has preferable valuation & earnings, MBX or IVA?

Do institutionals and insiders hold more shares of MBX or IVA?

Do analysts prefer MBX or IVA?

Which has more risk & volatility, MBX or IVA?

Does the media refer more to MBX or IVA?

Is MBX or IVA more profitable?

Summary

How does Inventiva compare to HUTCHMED?

Which has preferable earnings & valuation, HCM or IVA?

Do institutionals & insiders hold more shares of HCM or IVA?

Do analysts rate HCM or IVA?

Does the media favor HCM or IVA?

Is HCM or IVA more profitable?

Which has more volatility and risk, HCM or IVA?

Summary

How does Inventiva compare to Supernus Pharmaceuticals?

Which has more risk and volatility, SUPN or IVA?

Does the media refer more to SUPN or IVA?

Which has better valuation and earnings, SUPN or IVA?

Is SUPN or IVA more profitable?

Do analysts prefer SUPN or IVA?

Do institutionals and insiders hold more shares of SUPN or IVA?

Summary

How does Inventiva compare to Liquidia?

Which has more risk & volatility, IVA or LQDA?

Do insiders and institutionals hold more shares of IVA or LQDA?

Do analysts prefer IVA or LQDA?

Does the media refer more to IVA or LQDA?

Which has higher earnings & valuation, IVA or LQDA?

Is IVA or LQDA more profitable?

Summary

How does Inventiva compare to Harmony Biosciences?

Which has more volatility and risk, IVA or HRMY?

Does the media prefer IVA or HRMY?

Which has stronger earnings & valuation, IVA or HRMY?

Is IVA or HRMY more profitable?

Do analysts recommend IVA or HRMY?

Do institutionals & insiders hold more shares of IVA or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools